top of page



  • The National Cancer Institute has awarded Proteovista's SBIR Grant, Site-Specific Incorporation of Phosphorylation Modifications on the SNAP-Tide High Density Peptide Array


  • Proteovista has been awarded a SBIR Advance Phase I Match Grant from the Wisconsin Center for Technology Commercialization, August 2017


  • Proteovista presented "High Throughput Analysis of the DNA Binding Specificity of Estrogen Receptor and Estrogen Related Receptor Complexes," Keystone Symposium Nuclear Receptors: Full Throttle in Snowbird, UT.


  • Proteovista presented invited talk to U.S. Representative Mark Pocan at University Research Park. 

  • Proteovista presented “High Density Peptide Arrays for Cancer-Related Post-Translational Modifications" at the IMAT Symposium in Bethesda, MD.

  • Proteovista presented "Discovery of Small Molecule Modulators Targeting Estrogen Receptor-FoxA1-DNA Interactions Using SNAP-Screen DNA Arrays" at FASEB meeting in Big Sky, MT. 

  • Proteovista awarded Wisconsin Small Business Innovation Award for Outstanding Achievements. 


  • The National Institutes of Health has awarded Proteovista a three-year, $643,000 grant to develop a new microarray platform for identifying biomarkers associated with various cardiovascular diseases.

  • "SNP-SNAP Binding Arrays Reveal SNPs that Modulate Transcription Factor Interactions in Prostate Cancer" selected for a talk at the ENDO Society meeting in Chicago.

  • Proteovista Co-Founder prevails in lawsuit against VistaMotif LLC and Professor Aseem Ansari.

  • Proteovista presented "High Throughput Strategies to Identify Small Molecule Modulators of Estrogen Receptor - DNA Interactions" at the Keystone Symposia in Taos, New Mexico. 

  • Proteovista is awarded a three year R21 grant by the NIH for the development of a high density peptide array to study human post-translational modifications.


  • Illumavista Biosciences LLC has changed its name to Proteovista LLC.


  • The United States Department of Defense grants a Pilot Award in ovarian cancer research to Proteovista LLC.

  • Proteovista launches its SNAP technology as a custom service.

  • Proteovista awarded Wisconsin Small Business Innovation Award for Outstanding Achievements.


  • Proteovista is awarded an NIH Phase I SBIR to develop novel breast cancer therapeutics

  • Protevista is awarded a highly competitive National Cancer Institute IMAT (Innovative Molecular Analysis Technologies) grant to study genetic variations in prostate cancer incidence.

  • Drs. Warren and Ozers give an invited research presentation at the Era of Hope Breast Cancer Research Conference sponsored by the Department of Defense and Congressionally Directed Medical Research Programs.


  • Principal Investigators, Drs. Warren and Ozers, completed Small Business Innovation Research (SBIR) Phase I in April 2010 and Department of Defense Concept Award in September 2010.

  • Collaborated on the Research Poster, "Effect of Bisphenol A on the Comprehensive DNA Recognition Profile of Estrogen-Related Receptor Gamma and Estrogen Receptor Alpha in Breast Cancer Cells," at the 92nd Annual Meeting of the Endocrine Society, San Diego CA, June 2010.

bottom of page